Key takeaways:The FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1, making it the first drug to directly target the underlying loss of orexin signaling. The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals America Inc’s application for Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults, marking the first time a medicine has been approved to treat the condition as a complete disorder. Orzeyful is the first drug to work by directly targeting the loss of orexin signaling, which causes the disease. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.” More on Narcolepsy Type 1:Photo: Takeda global headquarters, courtesy of media assets library